Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations
Hansa Medical AB (publ) announced today the appointment of Henk Doude van Troostwijk as Vice President, Commercial Operations to strengthen its management team.
Henk´s key focus will be on the company’s commercial assessments of its lead project IdeS, including market access, pricing and re-imbursement aspects. IdeS is now in Phase II clinical development focused on kidney transplantation in sensitized patients.
“We are very excited that Henk will engage in Hansa Medical, as we now start to prepare our commercialization strategy for IdeS”, said Göran Arvidson, President and CEO of Hansa Medical.
Henk has significant management experience in sales and marketing from the areas of transplantation and orphan drugs. Lately, Henk has served as Business Unit Director Oncology and Transplantation at Genzyme and most recently as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Henk holds an MBA from Henley Management College at the University of Reading, UK
Besides Henk, the management team of Hansa Medical consists of:
Göran Arvidson President and CEO
Christian Kjellman Senior Vice President, Research and Development
Emanuel Björne Vice President, Business Development and Investor Relations
Steven Glazer Vice President, Chief Medical Officer
Eva-Maria Joed Vice President, Chief Financial Officer
Lena Winstedt Vice President, Project Management
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.